IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#445
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$9.8B
Thierry Bernard
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring.
Headcount
6.0K
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = QGEN ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$QGEN QIAGEN N.V. | 63 | 68 | 74 | 57 | 124.9x | 8.4x | 9.4% | 5.9% | 48.9% | 4.9% | 4.2% | 0.7% | 0.0% | 39.0x | $9.8B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
QIAGEN N.V. (QGEN) receives a "Hold" rating with a composite score of 62.7/100. It ranks #445 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
HQ Base
Venlo,
In-line with peers — no strong momentum signal
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for QGEN.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 68 | 74 | -6DRAG |
| MOMENTUM | 57 | 48 | +9ALPHA |
| VALUATION | 74 | 71 | +3NEUTRAL |
| INVESTMENT | 59 | 97 | -38DRAG |
| STABILITY | 92 | 95 | -3NEUTRAL |
| SHORT INT | 60 | 69 | -9DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC 6.7% vs WACC 8.8% (spread -2.0%)
GM 49% vs sector 43%, OM 5% vs sector 1%
Capital turnover 2.72x, R&D intensity 9.8%
Rev growth 1%, 9yr history
Interest coverage 2.2x, Net debt/EBITDA 2.3x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate QIAGEN N.V. (QGEN) as a Hold with a composite score of 62.7/100 at a current price of $48.51. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
QIAGEN N.V. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 62.7/100 places it at rank #445 in our full universe.
Narrow
Low
Poor
Undervalued
Gross margins of 49% signal strong pricing power.
Value factor score of 74 suggests attractive pricing.
Stable competitive position in a defensive sector.
Elevated P/E ratio of 124.9x leaves little room for execution misses.
Vulnerability to macroeconomic shocks and interest rate volatility.
QIAGEN N.V. represents a hold based on multi-factor quantitative performance.
Our model assigns QIAGEN N.V. a Hold rating, with a composite score of 62.7/100 and 3 out of 5 stars. Ranked #445 of 7,333 stocks, QGEN presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
QGEN earns a quality score of 68/100, indicating above-average business quality. The company reports a return on equity of 9.4% (sector avg: -2.5%), gross margins of 48.9% (sector avg: 42.5%), net margins of 4.2% (sector avg: -0.2%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
QGEN carries a solid value score of 74/100, pointing to an attractively priced stock relative to peers. Key valuation metrics include a P/E ratio of 124.87x, an EV/EBITDA of 8.42x, a P/B ratio of 2.81x. This score suggests reasonable compensation for the risks involved, with potential upside if the market recognizes the stock's underlying worth.
With an investment score of 59/100, QGEN exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 0.7% vs. a sector average of 5.9% and a return on assets of 5.9% (sector: -0.1%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
QGEN demonstrates moderate momentum with a score of 57/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 0.7% year-over-year, while a beta of 0.46 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
QIAGEN N.V. earns an excellent stability score of 92/100, reflecting low price volatility and a conservatively managed balance sheet. Key stability metrics include a beta of 0.46 and a debt-to-equity ratio of 39.00x (sector avg: 0.2x). Stocks with this level of stability tend to act as portfolio anchors, providing downside protection during market corrections while still participating in broad market advances.
QGEN carries a short interest score of 60/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include elevated leverage (D/E: 39.00x). At $9.8B market cap (mid-cap), QIAGEN N.V. offers reasonable institutional liquidity.
QIAGEN N.V. is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #445 of 7,333 overall (94th percentile). Key comparisons include ROE of 9.4% exceeding the -2.5% sector median and operating margins of 4.9% above the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While QGEN currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Momentum (57) is the limiting factor — improvement here would lift the composite score most.
EV/EBITDA 27% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 478% BELOW SECTOR MEDIAN
Gross Margin 15% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
German life sciences company Qiagen is exploring strategic options including a potential sale, with renewed takeover interest from multiple U.S.-based strategic buyers. The company has engaged advisers as its supervisory board evaluates preliminary approaches. CEO Thierry Bernard's announced departure is seen as removing a key obstacle to a deal. Qiagen has attracted acquisition interest multiple times in recent years, including failed attempts from Thermo Fisher Scientific (2020, ~$12 billion), BioMérieux (2021), and Bio-Rad Laboratories (2022).
Multiplexing Breakthroughs, Automation, and Bioinformatics Convergence Position Protein Microarrays as a Strategic Imperative for Precision Medicine LeadersDelray Beach, FL, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Global Protein Microarrays Market is projected to surge from USD 1.00 billion in 2025 to USD 1.78 billion by 2030, advancing at a compound annual growth rate (CAGR) of 12.3% over the forecast period. This near-doubling of market value underscores a fundamental shift: protein-level insigh
If you are wondering whether Qiagen's current share price offers fair value or a potential gap to fundamentals, you are in the right place. The stock last closed at US$48.57, with returns of 22.1% over 1 year and 2.1% year to date. Over the past week and 30 days it saw declines of 3.7% and 12.7% respectively, which may have changed how the market views its risk and opportunity. Recent news flow around Qiagen has mainly focused on its role in molecular diagnostics and life sciences tools,...
SEATTLE, Wash. & VENLO, the Netherlands, February 19, 2026--Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing.